Interestingly, preclinical studies in murine SCLC models have demonstrated that the combination of AC133-specific CAR-T cells with both PD-1 blockade and CD73 inhibition resulted in enhanced tumor elimination and prolonged remission (91). Here, NT5E is linked to small cell lung carcinoma.